ストックスクリーナーアプリを入手
22.42
3.70%
0.80
アフターアワーズ：
22.42
前日終値:
$21.62
開ける：
$22.03
24時間の取引高:
588.62K
Relative Volume:
1.36
時価総額：
$925.53M
収益：
-
当期純損益:
$-136.98M
株価収益率:
-5.5771
EPS:
-4.02
ネットキャッシュフロー:
$-126.63M
1週間 パフォーマンス:
+5.01%
1か月 パフォーマンス:
+9.69%
6か月 パフォーマンス:
+32.27%
1年 パフォーマンス:
-16.65%
1日の値動き範囲:
$21.71
$23.40
1週間の範囲:
$20.00
$23.40
52週間の値動き範囲:
$15.47
$28.12
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Compare AVBP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
22.42 | 892.50M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | 開始されました | Truist | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 6.8%Still a Buy? - MarketBeat
Growth Prospects for the EGFR-NSCLC Market Analyzed - Intellectia AI
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 5.6%Here's Why - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Trading Systems Reacting to (AVBP) Volatility - Stock Traders Daily
Targets Report: Whats the profit margin of ArriVent BioPharma IncJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
$207B Market Shift: The Race for Fast Track Approval in Oncology - The Malaysian Reserve
$207B Market Shift: The Race for Fast Track Approval in Oncology (2026-02-05) - Seeking Alpha
Aug Catalysts: Is ASTC a play on infrastructure spending2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Breakouts Watch: Can ArriVent BioPharma Inc maintain sales growthJuly 2025 Retail & Fast Gain Stock Trading Tips - baoquankhu1.vn
Big Money Moves Out of ArriVent BioPharma - TipRanks
Is ArriVent BioPharma Inc. stock vulnerable to regulatory risks2025 Top Decliners & Long-Term Safe Return Strategies - mfd.ru
What’s next for ArriVent BioPharma Inc. stockTrade Ideas & Consistent Growth Equity Picks - mfd.ru
How Arrivent Biopharma Inc. (AVBP) Affects Rotational Strategy Timing - Stock Traders Daily
Death Cross: Does First Commonwealth Financial Corporation offer margin of safetyEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Pullback Watch: Will FOXF benefit from green energy policiesEarnings Beat & Scalable Portfolio Growth Ideas - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5.8%Here's What Happened - MarketBeat
JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
Notable Thursday Option Activity: AVBP, GRAL, APPN - Nasdaq
Fed Watch: What’s next for ArriVent BioPharma Inc. stock2025 Geopolitical Influence & AI Forecasted Stock Moves - baoquankhu1.vn
ArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLC - MSN
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 8.2%What's Next? - MarketBeat
Can ArriVent BioPharma Inc. stock resist market sell offs - bollywoodhelpline.com
Rate Cut: Should I trade or invest in Materialise NV Depositary ReceiptOil Prices & Stock Portfolio Risk Control - baoquankhu1.vn
Technical Analysis: Is ArriVent BioPharma Inc subject to activist investor interest2025 Earnings Impact & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Entry Recap: Will SHIP outperform tech stocksQuarterly Portfolio Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
(AVBP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 7.2%Should You Buy? - MarketBeat
Aug Drivers: Should you avoid Zura Bio Limited stock right nowEarnings Summary Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
Aug Volume: Can ArriVent BioPharma Inc. stock attract ESG capital inflowsJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - Улправда
Can ArriVent BioPharma Inc. stock attract ESG capital inflowsJuly 2025 Rallies & Entry Point Strategy Guides - Улправда
Will ArriVent BioPharma Inc. stock see insider buyingQuarterly Market Review & Fast Moving Stock Trade Plans - Улправда
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock By Investing.com - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 7.4%Here's What Happened - MarketBeat
Responsive Playbooks and the AVBP Inflection - Stock Traders Daily
ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring A 99.97% Potential Upside - DirectorsTalk Interviews
Firmonertinib Trial Aims to Crack a Long-Standing Lung Cancer Treatment Gap - MyChesCo
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha
(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2%What's Next? - MarketBeat
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug - Investing.com Australia
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating - Investing.com
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study - TipRanks
ArriVent BioPharma Begins Phase 3 Trial of Firmonertinib in Lung Cancer - marketscreener.com
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):